Phase II multicentre, double-blind, randomised trial of ustekinumab in adolescents with new-onset type 1 diabetes (USTEK1D): trial protocol

Introduction Most individuals newly diagnosed with type 1 diabetes (T1D) have 10%–20% of beta-cell function remaining at the time of diagnosis. Preservation of residual beta-cell function at diagnosis may improve glycaemic control and reduce longer-term complications. Immunotherapy has the potentia...

Full description

Bibliographic Details
Main Authors:	Gregory, JW, Carter, K, Cheung, WY, Holland, G, Bowen-Morris, J, Luzio, S, Dunseath, G, Tree, T, Yang, JHM, Marwaha, A, Ali, MA, Bashir, N, Hutchings, HA, Fegan, GW, Stenson, R, Hiles, S, Marques-Jones, S, Brown, A, Tatovic, D, Dayan, C
Format:	Journal article
Language:	English
Published:	BMJ Publishing Group 2021

Phase II multicentre, double-blind, randomised trial of ustekinumab in adolescents with new-onset type 1 diabetes (USTEK1D): trial protocol

Similar Items